Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors

Ophthalmologica

Volumn 227, Issue SUPPL. 1, 2012, Pages 2-10

  Chong, Victor ^a  

^a OXFORD EYE HOSPITAL   (United Kingdom)

Author keywords

Age related macular degeneration; Avastin; Diabetic macular edema; EYLEA; Lucentis; Macugen; Vascular endothelial growth factors

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; EYLEA; PEGAPTANIB; RANIBIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ARTICLE; CEREBROVASCULAR ACCIDENT; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EYE INFLAMMATION; HUMAN; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; STROKE; VEIN THROMBOSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; DIABETIC RETINOPATHY; HUMANS; MACULAR DEGENERATION; MACULAR EDEMA; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860156429     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000337152     Document Type: Article

References (53)

1. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676. (Pubitemid 36749215)
2. Ribatti D: From the discovery of vascular endothelial growth factor to the introduction of Avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti. Int J Dev Biol 2011; 55: 383-388.
3. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309. (Pubitemid 20066716)
4. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611. (Pubitemid 39099316)
5. Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB: Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991; 6: 1677-1683. (Pubitemid 21924273)
6. Takahashi H, Shibuya M: The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions (review). Clin Sci (Lond) 2005; 109: 227-241. (Pubitemid 41337127)
7. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-991.
8. Gerber HP, Condorelli F, Park J, Ferrara N: Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is upregulated by hypoxia. J Biol Chem 1997; 272: 23659-23667. (Pubitemid 27410939)
9. Park JE, Chen HH, Winer J, Houck KA, Ferrara N: Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269: 25646-25654.
10. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, et al: VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 2009; 106: 6152-6157.
11. Li Y, Zhang F, Nagai N, Tang Z, Zhang S, Scotney P, et al: VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest 2008; 118: 913-923. (Pubitemid 351364599)
12. Lohela M, Saaristo A, Veikkola T, Alitalo K: Lymphangiogenic growth factors, receptors and therapies. Thromb Haemost 2003; 90: 167-184. (Pubitemid 36992494)
13. Tolentino M: Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56: 95-113.
14. Ferrara N, Mass RD, Campa C, Kim R: Targeting VEGF-A to treat cancer and age-related macular degeneration (review). Annu Rev Med 2007; 58: 491-504. (Pubitemid 46706529)
15. Adamis AP, Shima DT: The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25: 111-118. (Pubitemid 40365933)
16. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, et al: Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-584. (Pubitemid 24285965)
17. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487. (Pubitemid 24356306)
18. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66-71. (Pubitemid 26026196)
19. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP: Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996; 114: 964-970. (Pubitemid 26271462)
20. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816. (Pubitemid 40051904)
21. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
22. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444. (Pubitemid 44511558)
23. Regeneron Pharmaceuticals. VEGF Trap-Eye - Ophthalmologic Drugs Advisory Committee, June 17, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisory- Committee/UCM259143.pdf (accessed Jan 2012).
24. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP: Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5: 123-132.
25. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599. (Pubitemid 27441066)
26. Ferrara N, Damico L, Shams N, Lowman H, Kim R: Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-870. (Pubitemid 44547437)
27. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, et al: Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293: 865-881. (Pubitemid 29527672)
28. Baca M, Presta LG, O'Connor SJ, Wells JA: Antibody humanization using monovalent phage display. J Biol Chem 1997; 272: 10678-10684. (Pubitemid 27181078)
29. Yu L, Liang XH, Ferrara N: Comparing protein VEGF inhibitors: in vitro biological studies. Biochem Biophys Res Commun 2011; 408: 276-281.
30. Meyer CH, Holz FG: Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab (review). Eye (Lond) 2011; 25: 661-672.
31. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179-2182. (Pubitemid 350181137)
32. Kim H, Robinson SB, Csaky KG: FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009; 15: 2803-2812.
33. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179-2182. (Pubitemid 350181137)
34. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-859. (Pubitemid 46635858)
35. Byeon SH, Kang SY: Pharmacokinetics. Ophthalmology 2009; 116: 168-169, author reply 169-170.
36. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400. (Pubitemid 38618122)
37. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J: Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62: 779-786.
38. Stewart MW: Predicted biologic activity of intravitreal bevacizumab. Retina 2007; 27: 1196-1200. (Pubitemid 350211524)
39. Stewart MW, Rosenfeld PJ: Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008; 92: 667-668. (Pubitemid 351684178)
40. Meyer CH, Krohne TU, Holz FG: Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 2011; 31: 1877-1884.
41. Meyer CH, Krohne TU, Holz FG: Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. Acta Ophthalmol 2012; 90: 68-70.
42. Sawada O, Kawamura H, Kakinoki M, Ohji M: Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1379-1381.
43. Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, et al: Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010; 51: 1606-1608.
44. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T: Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010; 94: 1215-1218.
45. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136. (Pubitemid 351398487)
46. Novartis. Lucentis prescribing information. 2006.
47. Gamulescu MA, Helbig H: Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J Ocul Pharmacol Ther 2010; 26: 213-216.
48. Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB: Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 2010; 149: 939-946.e1.
49. Schmidt-Erfurth U: Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf 2010; 9: 149-165.
50. Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, et al: Neovascular agerelated macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009; 116: 2393-2399.
51. CATT Research Group, Martin DF, Maguire MG, et al: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908.
52. Curtis LF, Hammill BG, Schulman KA, et al: Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128: 1273-1279, erratum 1623.
53. Gower EW, Chu L, Varma R, Klein R: Adverse event rates following intravitreal injection of Avastin or Lucentis for treating agerelated macular degeneration, poster 6644, ARVO 2011.